Amgen Inc. with ticker code (AMGN) have now 23 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The target price High/Low ranges between $350.00 and $185.00 calculating the average target price we see $287.91. Given that the stocks previous close was at $307.26 this indicates there is a potential downside of -6.3%. Also worth taking note is the 50 day moving average now sits at $274.48 and the 200 day MA is $252.30. The market capitalization for the company is 164.38B. The stock price is currently at: $307.15 USD
The potential market cap would be $154,027,931,680 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 21.83, revenue per share of $50.16 and a 7.86% return on assets.
Amgen Inc. is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. The Company’s marketed products portfolio includes Aranesp, ENBREL, Prolia (denosumab), Neulasta (pegfilgrastim), Otezla, XGEVA, Aranesp (darbepoetin alfa), KYPROLIS, Repatha (evolocumab), Nplate (romiplostim), Vectibix (panitumumab), MVASI (bevacizumab-awwb), Parsabiv (etelcalcetide), EPOGEN (epoetin alfa), KANJINTI (trastuzumab-anns), BLINCYTO (blinatumomab), Aimovig (erenumab-aooe), EVENITY (romosozumab-aqqg), AMGEVITATM (adalimumab), Sensipar/Mimpara (cinacalcet), NEUPOGEN (filgrastim), IMLYGIC (talimogene laherparepvec), Corlanor (ivabradine) and AVSOLA (infliximab-axxq), Evenity, LumaKras, Nplate, XGeva, and others. The Company focuses on human therapeutics for the treatment of serious illness in the areas of inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology and neuroscience.
